Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis

Nephron - Clinical Practice

Volumn 105, Issue 4, 2007, Pages

  Ozkaya, Ozan ^a   Buyan, Necla ^b   Bideci, Aysun ^b   Gonen, Sevim ^b   Ortac, Erol ^a   Fidan, Kibriya ^b   Cinaz, Peyami ^b   Soylemezoglu O ^b  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Chronic renal impairment; Dialysis; Osteoprotegerin; RANKL serum levels; RANKL OPG system; Renal osteodystrophy; Serum ghrelin in children

Indexed keywords

GHRELIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ARTICLE; BIOLOGICAL ACTIVITY; BONE REMODELING; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RENAL OSTEODYSTROPHY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; OSTEOPROTEGERIN; PEPTIDE HORMONES; PROGNOSIS; RANK LIGAND; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS;

EID: 33947637285     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099005     Document Type: Article

References (32)

1. Hruska K: New concepts in renal osteodystrophy. Nephrol Dial Transplant 1998;13:2755-2760.
2. Monier-Faugere MC, Malluche HH: Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327-332.
3. Turk S, Akbulut M, Y?ld?z A, Gurbilek M, Gonen S, Tombul Z, Yeksan M: Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 2002;90:188-194.
4. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL: IL-1β, TNF-α, TGF-β, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int 2003;63:899-907.
5. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
7. Yasuda H, Shima N, Nakagawa, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K: A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999;1:109-113.
8. Theill LE, Boyle WJ, Penninger JM: RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
9. Avbersek-Luznik I, Balon BP, Rus I, Marc J: Increased bone resorption in HD patients: Is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 2005;20:566-570.
10. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M: Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegeria) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-532.
11. Avbersek-Luznik I, Malesic I, Rus I, Marc J: Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002;40:1019-1023.
12. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E: Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002;17:233-238.
13. Nakazato M, Murakami N, Date Y: A role for ghrelin in the central regulation of feeding. Nature 2000;409:194-198.
14. De Ambrogi M, Volpe S, Tamanini C: Ghrelin: central and peripheral effects of a novel peptidyl hormone. Med Sci Monit 2003;9:217-224.
15. Ayala ER, Pecoits-Filho R, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P: Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 2004;19:421-426.
16. Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, Takaya K, Hosoda H, Kojima M, Kangawa K, Nakao K: Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002;13:2748-2752.
17. Barazzoni R, Zanetti M, Biolo G, Guarnieri G: Metabolic effects of ghrelin and its potential implications in uremia. J Ren Nutr 2005;15:111-115.
18. Caminos JE, Gualillo O, Lago F, Otero M, Blanco M, Gallego R, Garcia-Caballero T, Goldring MB, Casanueva FF, Gomez-Reino JJ, Dieguez C: The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted by chondrocytes. Endocrinology 2005;146:1285-1292.
19. Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C, Cocchi D: Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 2005;184:249-256.
20. Coates PS, Fernstrom JD, Fernstrom MH, Schauer PR, Greenspan SL: Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004;89:1059-1060.
21. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987;34:571-590.
22. Abrahamsen B, Hjelmborg J, Kostenuik P, Stilgren L, Kyvik K, Adamu S, Brixen K, Langdahl B: Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 2005;36:727-735.
23. Kazama JJ: Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens 2004;13:411-415.
24. Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H, Watanabe I, Katayama A, Haba T, Uchida K, Fukagawa M: Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 2001;38:(suppl 1):S175-S177.
25. Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F: Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: Is there a potential modulating role for OPG/RANK-L in bone injury? J Rheumatol 2004;31:986-991.
26. Aguilera A, Cirugeda A, Amair R, Sansone G, Alegre L, Codoceo R, Bajo MA, del Peso G, Diez JJ, Sanchez-Tomero JA, Selgas R: Ghrelin plasma levels and appetite in peritoneal dialysis patients. Adv Perit Dial 2004;20:194-199.
27. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS, Kim SY: Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone 2005;37:359-369.
28. Misra M, Miller KK, Stewart V, Hunter E, Kuo K, Herzog DB, Klibanski A: Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. Clin Endocrinol Metab 2005;90:5082-5087.
29. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, Takeda S, Takeuchi Y, Fukumoto S, Kangawa K, Nagata K, Kojima M: Ghrelin directly regulates bone formation J Bone Miner Res 2005;20:790-798.
30. Delhanty PJ, van der Eerden BC, van der Velde M, Gauna C, Pols HA, Jahr H, Chiba H, van der Lely AJ, van Leeuwen JP: Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol 2006;188:37-47.
31. Pantouli E, Boehm MM, Koka S: Inflammatory cytokines activate p38-MAPK to induce osteoprotegerin synthesis by MG-63 cells. Biochem Biophys Res Commun 2005;329:224-229.
32. Tazoe M, Mogi M, Goto S, Togari A: Involvement of p38-MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. Arch Oral Biol 2003;48:615-619.